January NCI Office of Advocacy Relations Update

National Cancer Institute sent this bulletin at 01/06/2020 02:05 PM EST
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 

 

You are subscribed to the Office of Advocacy Relations Update from the National Cancer Institute. Read highlights of the latest news and upcoming events happening at NCI. 

 

Upcoming Events

National Cancer Advisory Board (NCAB) Meeting, February 11, 2020

Frederick National Laboratory Advisory Committee (FNLAC) Meeting, February 19, 2020

Note: Videocasts for advisory board meetings will be available at https://videocast.nih.gov/ the day of the meeting and will be archived shortly after for viewing on demand.

Upcoming NCI Director Appearances

  

Dr. Sharpless will be speaking at the following in January:

 

Stanford Cancer Institute, January 10, 2020 (Stanford, CA)

For ongoing updates, follow @NCIDirector on Twitter.

Recent NCI Announcements

  

Immunotherapy drug improves outcomes for some children with relapsed leukemia (December 10, 2019)

New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.

Recent Cancer Currents Posts

  

Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health (December 23, 2019)

Dr. Teresa Woodruff discusses the field that connects oncology with reproductive health, and the Oncofertility Consortium’s efforts to support clinicians, cancer patients, and families in understanding how cancer and its treatment affect fertility.

 

Anal Cancer Incidence and Deaths Are Rising in the United States (December 19, 2019)

The number of cases and deaths from anal cancer have been on the rise in the United States since 2001, according to a new study. The increases have been especially rapid in two segments of the population.

 

Surgery for Recurrent Ovarian Cancer Does Not Improve Survival (December 10, 2019)

Secondary surgery for women with recurrent ovarian cancer does not improve how long those women live, findings from a large trial show. The results call into question the current standard of practice for these patients.

 

Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial (December 5, 2019)

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.

 

Read more news at the Cancer Currents blog.